Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100)

Annals of Oncology

Volumn 24, Issue 7, 2013, Pages 1807-1812

  Loriot, Y ^a   Bianchini, D ^b   Ileana, E ^a   Sandhu, S ^b   Patrikidou, A ^a   Pezaro, C ^b   Albiges, L ^a   Attard, G ^b   Fizazi, K ^a   De Bono, J S ^b   Massard, C ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Abiraterone; CRPC; Enzalutamide; Hormonal manipulations

Indexed keywords

ABIRATERONE ACETATE; DOCETAXEL; ENZALUTAMIDE; PREDNISOLONE; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; AMNESIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE DISEASE; CANCER GROWTH; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL ARTICLE; CLINICAL ASSESSMENT; DRUG EFFICACY; DRUG TOLERABILITY; EDEMA; HOT FLUSH; HUMAN; HYPOKALEMIA; LYMPHADENOPATHY; MALE; METASTASIS POTENTIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN ANALYSIS; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

EID: 84882789820     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdt136     Document Type: Article

References (22)

1. Ferlay J, Autier P, Boniol M et al. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 2007; 18: 581-92.
2. Siegel R, DeSantis C, Virgo K et al. Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin 2012; 62: 220-41.
3. Attard G, Reid AH, A'Hern R et al. Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J Clin Oncol 2009; 27: 3742-8.
4. Tran C, Ouk S, Clegg NJ et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 2009; 324: 787-90.
5. Massard C, Fizazi K. Targeting continued androgen receptor signaling in prostate cancer. Clin Cancer Res 2011; 17: 3876-3883.
6. de Bono JS, Logothetis CJ, Molina A et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011; 364: 1995-2005.
7. Fizazi K, Scher HI, Molina A et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA- 301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 2012; 13: 983-992.
8. Scher HI, Beer TM, Higano CS et al. Antitumour activity of MDV3100 in castrationresistant prostate cancer: a phase 1-2 study. Lancet 2010; 375: 1437-46.
9. Scher HI, Fizazi K, Saad F et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012; 367: 1187-97.
10. Scher HI, Halabi S, Tannock I et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 2008; 26: 1148-59.
11. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-216.
12. Noonan K, Ellard S, Chi K. Clinical activity of abiraterone acetate (AA) after progression on MDV3100 in patients with metastatic castration-resistant prostate cancer (mCRPC). Ann Oncol 2012; 23(suppl 9): ix294-ix318: Abstr 925P.
13. Mostaghel EA, Marck BT, Plymate SR et al. Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants. Clin Cancer Res 2011; 17: 5913-25.
14. Hu R, Lu C, Mostaghel EA et al. Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer. Cancer Res 2012; 72: 3457-62.
15. Richards J, Lim AC, Hay CW et al. Interactions of abiraterone, eplerenone, and prednisolone with wild-type and mutant androgen receptor: a rationale for increasing abiraterone exposure or combining with MDV3100. Cancer Res 2012; 72: 2176-82.
16. Efstathiou E, Titus MA, Tsavachidou D et al. MDV3100 effects on androgen receptor (AR) signaling and bone marrow testosterone concentration modulation: a preliminary report. J Clin Oncol 2011; 29: (suppl; abstr 4501).
17. Cai C, Chen S, Ng P et al. Intratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitors. Cancer Res 2011; 71: 6503-13.
18. Efstathiou E, Titus M, Tsavachidou D et al. Effects of abiraterone acetate on androgen signaling in castrate-resistant prostate cancer in bone. J Clin Oncol 2012; 30: 637-43.
19. Carver BS, Chapinski C, Wongvipat J et al. Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell 2011; 19: 575-86.
20. Zhu ML, Horbinski CM, Garzotto M et al. Tubulin-targeting chemotherapy impairs androgen receptor activity in prostate cancer. Cancer res 2010; 70: 7992-8002.
21. Mezynski J, Pezaro C, Bianchini D et al. Antitumour activity of docetaxel following treatment with the CYP17A1 inhibitor abiraterone: clinical evidence for cross-resistance? Ann Oncol 2012; 23: 2943-2947.
22. Albiges L, Le Moulec S, Loriot Y et al. Response to cabazitaxel in the postchemotherapy setting in CRPC patients previously treated with docetaxel and abiraterone acetate. Ann Oncol 2012; 23: S294-iS318, (suppl 9).